DRUGS IN R&D

简称 DRUGS R&D ·New Zealand ·出版周期 4 issues a year, 2010- ·年均收录 0 篇

2.1

最新影响因子

100.00%

自引率

容易

投稿难度

期刊简介

Drugs in Research & Development是一本专注于药物研发领域的学术期刊，ISSN号为1174-5886，由Adis International出版，出版周期和出版地信息未明确公开。该期刊的影响因子未被广泛报道，可能较低或未被主流索引收录。它并非开放获取（OA）期刊，也未列入SCI或中科院分区。期刊的发文特点集中于药物研发的早期到临床阶段研究，涵盖药物化学、药理学、临床试验及相关技术创新。其研究领域包括新药发现、药物安全性评价和转化医学等。质量方面，由于缺乏高影响因子和权威索引收录，其学术影响力可能有限，存在一定投稿风险，适合关注细分领域的研究者投稿，但需谨慎评估其学术认可度。

影响因子趋势

近期发表

Comparative Pharmacokinetics of Trientine Dihydrochloride Capsules: A Randomized, Open-Label, Reference-Controlled, Two-Period Crossover Study in Healthy Volunteers 2026-09-09

Study on the Pharmacokinetics and Pharmacodynamics of Transdermal Estradiol Gel Administered Repeatedly in Postmenopausal Women 2026-09-09

Optimizing Drug-Resistant Epilepsy Management: Cenobamate’s role in the Surgery/Neuromodulation Pathway 2026-07-22

Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation 2026-06-09

Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study 2026-07-01

A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors 2026-05-24

Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies 2026-05-22

Response to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema” 2026-03-28

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies 2026-03-28

Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms 2026-04-03